Abstract
BackgroundSmall-volume resuscitation can rapidly correct hypovolemia. Hyperoncotic albumin solutions, long in clinical use, are suitable for small-volume resuscitation; however, their clinical benefits remain uncertain.MethodsRandomized clinical trials comparing hyperoncotic albumin with a control regimen for volume expansion were sought by multiple methods, including computer searches of bibliographic databases, perusal of reference lists, and manual searching. Major findings were qualitatively summarized. In addition, a quantitative meta-analysis was performed on available survival data.ResultsIn all, 25 randomized clinical trials with a total of 1,485 patients were included. In surgery, hyperoncotic albumin preserved renal function and reduced intestinal edema compared with control fluids. In trauma and sepsis, cardiac index and oxygenation were higher after administration of hydroxyethyl starch than hyperoncotic albumin. Improved treatment response and renal function, shorter hospital stay and lower costs of care were reported in patients with liver disease receiving hyperoncotic albumin. Edema and morbidity were decreased in high-risk neonates after hyperoncotic albumin administration. Disability was reduced by therapy with hyperoncotic albumin in brain injury. There was no evidence of deleterious effects attributable to hyperoncotic albumin. Survival was unaffected by hyperoncotic albumin (pooled relative risk, 0.95; 95% confidence interval 0.78 to 1.17).ConclusionIn some clinical indications, randomized trial evidence has suggested certain benefits of hyperoncotic albumin such as reductions in morbidity, renal impairment and edema. However, further clinical trials are needed, particularly in surgery, trauma and sepsis.
Highlights
The advantages of small-volume resuscitation in rapidly correcting hypovolemia and interrupting the pathological processes leading to multi-organ failure and other poor outcomes are well recognized [1]
Randomized clinical trials comparing hyperoncotic albumin with a control regimen for volume expansion were sought by multiple methods, including computer searches of bibliographic databases, perusal of reference lists, and manual searching
Cardiac index and oxygenation were higher after administration of hydroxyethyl starch than hyperoncotic albumin
Summary
The advantages of small-volume resuscitation in rapidly correcting hypovolemia and interrupting the pathological processes leading to multi-organ failure and other poor outcomes are well recognized [1]. The use of hyperosmolar solutions containing artificial colloid for small-volume resuscitation has been described previously [2]. Another fluid type suitable for small-volume resuscitation is hyperoncotic (20 to 25%) albumin. Hyperoncotic albumin solutions, long in clinical use, are suitable for small-volume resuscitation; their clinical benefits remain uncertain
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have